

Monika A Niewczas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8316432/publications.pdf>

Version: 2024-02-01

36
papers

3,542
citations

236925

25
h-index

377865

34
g-index

36
all docs

36
docs citations

36
times ranked

4593
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes. <i>Kidney International</i> , 2022, 102, 370-381.	5.2	17
2	Serum Orotidine: A Novel Biomarker of Increased CVD Risk in Type 2 Diabetes Discovered Through Metabolomics Studies. <i>Diabetes Care</i> , 2022, 45, 1882-1892.	8.6	5
3	A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders. <i>Kidney International</i> , 2021, 99, 725-736.	5.2	11
4	Circulating short and medium chain fatty acids are associated with normoalbuminuria in type 1 diabetes of long duration. <i>Scientific Reports</i> , 2021, 11, 8592.	3.3	6
5	Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2331-2351.	6.1	20
6	Circulating Osteoprotegerin in Chronic Kidney Disease and All-Cause Mortality. <i>International Journal of General Medicine</i> , 2021, Volume 14, 2413-2420.	1.8	12
7	A biomimetic five-module chimeric antigen receptor (^{5M} CAR) designed to target and eliminate antigen-specific T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28950-28959.	7.1	19
8	Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy. <i>Diabetes Care</i> , 2019, 42, 1263-1273.	8.6	72
9	A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. <i>Nature Medicine</i> , 2019, 25, 805-813.	30.7	260
10	IL 6 but not TNF is linked to coronary artery calcification in patients with chronic kidney disease. <i>Cytokine</i> , 2019, 120, 9-14.	3.2	34
11	Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes. <i>Diabetes</i> , 2018, 67, 1013-1023.	0.6	73
12	Markers of early progressive renal decline in type 2 diabetes suggest different implications for aetiological studies and prognostic tests development. <i>Kidney International</i> , 2018, 93, 1198-1206.	5.2	88
13	SP395 INTERLEUKIN 6 AND CALCIUM SCORE PREDICT THE RISK OF 5-YEAR ALL-CAUSE MORTALITY IN CKD PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i479-i480.	0.7	0
14	Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. <i>Diabetes Care</i> , 2017, 40, 383-390.	8.6	88
15	Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. <i>Kidney International</i> , 2017, 92, 258-266.	5.2	38
16	Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. <i>Nature Medicine</i> , 2017, 23, 753-762.	30.7	337
17	Metabolomic Profiling in Individuals with a Failing Kidney Allograft. <i>PLoS ONE</i> , 2017, 12, e0169077.	2.5	39
18	Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. <i>Diabetes Care</i> 2017;40:383-390. <i>Diabetes Care</i> , 2017, 40, e109-e110.	8.6	0

#	ARTICLE	IF	CITATIONS
19	Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. <i>Kidney International</i> , 2016, 89, 226-234.	5.2	57
20	Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. <i>Kidney International</i> , 2016, 89, 459-467.	5.2	101
21	Genetic Variant at the <i>GLUL</i> Locus Predicts All-Cause Mortality in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2015, 64, 2658-2663.	0.6	24
22	Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. <i>Kidney International</i> , 2015, 87, 812-819.	5.2	103
23	Interleukin-10+ Regulatory B Cells Arise Within Antigen-Experienced CD40+ B Cells to Maintain Tolerance to Islet Autoantigens. <i>Diabetes</i> , 2015, 64, 158-171.	0.6	80
24	Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5-18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria. <i>Diabetes Care</i> , 2014, 37, 2601-2608.	8.6	43
25	Role of Podocyte B7-1 in Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1415-1429.	6.1	114
26	Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria. <i>Diabetes Care</i> , 2014, 37, 226-234.	8.6	219
27	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. <i>Kidney International</i> , 2014, 85, 1214-1224.	5.2	182
28	Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1. <i>PLoS ONE</i> , 2013, 8, e58007.	2.5	34
29	Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, F157-F162.	2.7	21
30	The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. <i>Kidney International</i> , 2012, 82, 589-597.	5.2	120
31	Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 507-515.	6.1	388
32	Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 516-524.	6.1	307
33	Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl- β -D-glucosaminidase. <i>Kidney International</i> , 2011, 79, 464-470.	5.2	202
34	Risk for ESRD in Type 1 Diabetes Remains High Despite Renoprotection. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 545-553.	6.1	166
35	High-Normal Serum Uric Acid Is Associated with Impaired Glomerular Filtration Rate in Nonproteinuric Patients with Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 706-713.	4.5	130
36	Association of Urinary Inflammatory Markers and Renal Decline in Microalbuminuric Type 1 Diabetics. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 789-797.	6.1	132